Tapimmune Inc (TPIV) 0.2510 $TPIV
TapImmune CEO Discusses Company's Clinical Programs in Recent Print and Radio Interviews
PR Newswire - Mon Nov 24, 8:06AM CST
TapImmune, Inc. (OTCQB: TPIV), is pleased to point its shareholders to the following press articles published recently in which TapImmune CEO Dr Glynn Wilson has been interviewed. In light of the company's recent news about the establishment of a Phase 2 collaboration and advancement of both clinical programs, the company would like to direct its shareholders to these articles and interviews where Dr Wilson has discussed the progression of clinical trials and TapImmune's technology approach.
Published Review and Analyst Report Boost TapImmune Shares
Marketwired - Wed Nov 19, 3:21PM CST
TapImmune, Inc. (OTCQB: TPIV) was mentioned positively by analysts reacting to recently published comments by Chairman & CEO Glynn Wilson, Ph.D.
VGTI Florida to Collaborate with TapImmune to Advance Targeted Breast and Ovarian Cancer Vaccines into Phase II Clinical Trials
Business Wire - Tue Nov 18, 10:40AM CST
The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, today announced a new collaborative research agreement with TapImmune, Inc. (OTCQB: TPIV), forming a partnership to advance TapImmune's proprietary, targeted cancer vaccines into mid-stage, Phase II human clinical trials for the treatment of breast and ovarian cancers.
TapImmune Announces Phase II Clinical Trials Collaboration With VGTI Florida to Advance Breast and Ovarian Cancer Vaccines
PR Newswire - Tue Nov 18, 9:00AM CST
TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, forming a partnership to advance TapImmune's proprietary, cancer vaccines into Phase II human clinical trials for the treatment of breast and ovarian cancers.
Could This Emerging Drug Developer Really Be Worth A Billion Dollars In Five Years?
ACCESSWIRE - Mon Nov 17, 7:02AM CST
Los Angeles, CA / ACCESSWIRE / November 17, 2014 / Chief Executive Officers of publicly traded companies are often warned not speculate about the future valuation of their firms and that's precisely part of the reason investors are looking more closely at the recent "on the record" statements made by TapImmune's (OTCBB:TPIV) Dr. Glynn Wilson to the Life Sciences Intellectual Property Review.
KITE: 51.96 (+0.45)
The Life Sciences Report Interviews SeeThruEquity Regarding Microcap Life Sciences Companies
ACCESSWIRE - Wed Nov 05, 8:24AM CST
New York, NY / ACCESSWIRE / November 5, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it was recently interviewed by The Life Sciences Report regarding the microcap market for life sciences companies, during which SeeThruEquity analysts discussed DelMar Pharmaceuticals Inc. (OTCQB: DMPI), Manhattan Scientifics Inc. (OTCQB: MHTX) and TapImmune Inc. (OTCQB: TPIV).
The most undervalued, yet comprehensive cancer immunotherapy in development?
ACCESSWIRE - Mon Nov 03, 7:03AM CST
Los Angeles, CA / ACCESSWIRE / November 3, 2014 / The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.
INO: 9.11 (-0.09), NWBO: 5.58 (+0.04), DNDN: 0.13 (-0.02), GALE: 1.49 (-0.02)
Time Magazine Warns Against Investing In Certain "Ebola Stocks"
ACCESSWIRE - Tue Oct 28, 8:22AM CDT
LOS ANGELES, CA / ACCESSWIRE / October 28, 2014 / Time Magazine is today warning investors that while developmental stage pharmas like Inovio Pharmaceuticals (NASDAQ:INO , NewLink Genetics Corp. (NASDAQ:NLNK), Tekmira Pharmaceuticals (NASDAQ:TKMR) and Sarepta Therapeutics (NASDAQ:SRPT) have all generated significant interest among stock market investors lately, there are good reasons to shy away from buying into experimental Ebola treatment therapies. But how can this be?
INO: 9.11 (-0.09), MRK: 57.46 (+0.25), PFE: 31.42 (-0.03), SRPT: 13.88 (+0.47), NLNK: 39.08 (+1.36), TKMR: 13.97 (+0.14), GSK: 42.85 (+0.11), NVS: 93.91 (+0.66)
TapImmune Provides Update on PolyStart(TM) Vaccine Platform Applicable to Cancer and Infectious Disease
Business Wire - Wed Oct 22, 7:30AM CDT
TapImmune, Inc. (OTCBB:TPIV), provides an update on the status of its PolyStart(TM) vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus. While the current focus of the Company's PolyStart technology is on TapImmune's cancer program (e.g., Her2/neu and folate receptor alpha antigens), the Company none-the-less strongly reaffirms that this core technology has widespread applicability in the development of vaccines for viral disease.
What's Next: Investors Place Ebola Pandemic Stock Bets
ACCESSWIRE - Mon Oct 06, 6:59AM CDT
Los Angeles, CA / October 6, 2014 / The recent outbreaks of Ebola in Africa and the first case found in the U.S. have also heightened the FDA's awareness of disease outbreaks and the need for stronger safety measures, but nothing gets investors salivating more that and constant media attention.
INO: 9.11 (-0.09), HEB: 0.22 (-0.02), TKMR: 13.97 (+0.14)
SeeThruEquity Issues Company Update on TapImmune Highlighting Positive Clinical Trial Data
ACCESSWIRE - Thu Sep 18, 8:03AM CDT
SeeThruEquity maintains price target of $6.97 per share and reiterates compelling valuation based on a number of factors including positive interim data on its Phase I clinical trial of folate receptor alpha antigens in ovarian and breast cancer
TapImmune Releases Positive Interim Data on Phase I Clinical Trial of Folate Receptor Alpha Antigens in Ovarian and Breast Cancer
Business Wire - Tue Sep 16, 7:30AM CDT
TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of 5 naturally processed folate receptor alpha Class II antigenic epitopes. All five of the constituent peptides were found to be immunogenic and all patients developed immune responses to at least one and in most cases more than one of the vaccine peptides.
TapImmune, Inc. to Present at SeeThruEquity Microcap Conference
ACCESSWIRE - Thu Sep 04, 8:01AM CDT
Seattle, WA / ACCESSWIRE / September 4, 2014 / TapImmune, Inc. (OTCQB: TPIV), announces that company executives will attend and present at the SeeThruEquity Microcap Investor Conference to be held Thursday September 11th at the Convene Times Square, New York City. The presentation is scheduled for 10:00AM ET.
TapImmune Inc to Present at 16th Annual Rodman & Renshaw Healthcare Conference
ACCESSWIRE - Wed Sep 03, 9:42AM CDT
Seattle WA / ACCESSWIRE / September 3, 2014 / TapImmune, Inc. (OTCQB: TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease, will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The presentation will take place Wednesday, September 10th at 2:30 p.m. EDT in the Kennedy I Salon (4th floor) at the New York Palace Hotel in New York City.
SeeThruEquity Issues Update Note on TapImmune Highlighting New Grant Funded Clinical Trial and Recent Capital Raise of $2 Million
ACCESSWIRE - Tue Aug 19, 7:51AM CDT
New York, NY / ACCESSWIRE / August 19, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (OTCQB: TPIV).
TapImmune, Inc. Announces $2 Million Registered Direct Offering
Business Wire - Mon Aug 11, 11:21AM CDT
TapImmune, Inc. (the "Company"
, (OTCQB:TPIV), today announced that it has entered into a definitive agreement with an institutional investor for a registered direct placement of $2,000,000 of common stock at a price of $1.06 per share.
TapImmune's New Clinical Trial in Advanced Stage Ovarian Cancer Expands the Use of Folate Receptor Alpha Peptide Antigens
Business Wire - Thu Aug 07, 8:23AM CDT
TapImmune Inc. (OTCQB:TPIV) is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial ovarian cancer has started at the Mayo Clinic, Rochester, MN. The folate receptor alpha peptides being used in this study are the same ones that are being used in a current Phase I study in breast and ovarian cancer. Folate receptor alpha is over a 100 fold elevated in 90% of ovarian cancer cells and is thus an excellent target for immunotherapy.
TapImmune Prevails in Legal Dispute with Michael Gardner
Business Wire - Thu Jul 24, 8:38AM CDT
TapImmune Inc. (OTCQB:TPIV), announces successful outcome of proceedings against Michael Gardner after almost 2 years of litigation.
New Immunotherapy Technologies Provide Hope In Breast and Ovarian Cancer
ACCESSWIRE - Wed Jul 23, 7:06AM CDT
Los Angeles / ACCESSWIRE / July 23, 2014 / Last month, TapImmune Inc. (OTCQB: TPIV) announced that Dr. Keith Knutson, PhD had been appointed to chair the company's scientific advisory board.
SeeThruEquity Issues Company Note on TapImmune Highlighting Valuation as Compared with Peers
ACCESSWIRE - Tue Jul 01, 8:02AM CDT
New York, NY / ACCESSWIRE / July 1, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company note on TapImmune Inc. (OTCQB: TPIV).
JNJ: 104.59 (+0.31), KITE: 51.96 (+0.45), GALE: 1.49 (-0.02)
TapImmune CEO Discusses Company's Clinical Programs in Recent Print and Radio Interviews
PR Newswire - Mon Nov 24, 8:06AM CST
TapImmune, Inc. (OTCQB: TPIV), is pleased to point its shareholders to the following press articles published recently in which TapImmune CEO Dr Glynn Wilson has been interviewed. In light of the company's recent news about the establishment of a Phase 2 collaboration and advancement of both clinical programs, the company would like to direct its shareholders to these articles and interviews where Dr Wilson has discussed the progression of clinical trials and TapImmune's technology approach.
Published Review and Analyst Report Boost TapImmune Shares
Marketwired - Wed Nov 19, 3:21PM CST
TapImmune, Inc. (OTCQB: TPIV) was mentioned positively by analysts reacting to recently published comments by Chairman & CEO Glynn Wilson, Ph.D.
VGTI Florida to Collaborate with TapImmune to Advance Targeted Breast and Ovarian Cancer Vaccines into Phase II Clinical Trials
Business Wire - Tue Nov 18, 10:40AM CST
The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, today announced a new collaborative research agreement with TapImmune, Inc. (OTCQB: TPIV), forming a partnership to advance TapImmune's proprietary, targeted cancer vaccines into mid-stage, Phase II human clinical trials for the treatment of breast and ovarian cancers.
TapImmune Announces Phase II Clinical Trials Collaboration With VGTI Florida to Advance Breast and Ovarian Cancer Vaccines
PR Newswire - Tue Nov 18, 9:00AM CST
TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, forming a partnership to advance TapImmune's proprietary, cancer vaccines into Phase II human clinical trials for the treatment of breast and ovarian cancers.
Could This Emerging Drug Developer Really Be Worth A Billion Dollars In Five Years?
ACCESSWIRE - Mon Nov 17, 7:02AM CST
Los Angeles, CA / ACCESSWIRE / November 17, 2014 / Chief Executive Officers of publicly traded companies are often warned not speculate about the future valuation of their firms and that's precisely part of the reason investors are looking more closely at the recent "on the record" statements made by TapImmune's (OTCBB:TPIV) Dr. Glynn Wilson to the Life Sciences Intellectual Property Review.
KITE: 51.96 (+0.45)
The Life Sciences Report Interviews SeeThruEquity Regarding Microcap Life Sciences Companies
ACCESSWIRE - Wed Nov 05, 8:24AM CST
New York, NY / ACCESSWIRE / November 5, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it was recently interviewed by The Life Sciences Report regarding the microcap market for life sciences companies, during which SeeThruEquity analysts discussed DelMar Pharmaceuticals Inc. (OTCQB: DMPI), Manhattan Scientifics Inc. (OTCQB: MHTX) and TapImmune Inc. (OTCQB: TPIV).
The most undervalued, yet comprehensive cancer immunotherapy in development?
ACCESSWIRE - Mon Nov 03, 7:03AM CST
Los Angeles, CA / ACCESSWIRE / November 3, 2014 / The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.
INO: 9.11 (-0.09), NWBO: 5.58 (+0.04), DNDN: 0.13 (-0.02), GALE: 1.49 (-0.02)
Time Magazine Warns Against Investing In Certain "Ebola Stocks"
ACCESSWIRE - Tue Oct 28, 8:22AM CDT
LOS ANGELES, CA / ACCESSWIRE / October 28, 2014 / Time Magazine is today warning investors that while developmental stage pharmas like Inovio Pharmaceuticals (NASDAQ:INO , NewLink Genetics Corp. (NASDAQ:NLNK), Tekmira Pharmaceuticals (NASDAQ:TKMR) and Sarepta Therapeutics (NASDAQ:SRPT) have all generated significant interest among stock market investors lately, there are good reasons to shy away from buying into experimental Ebola treatment therapies. But how can this be?
INO: 9.11 (-0.09), MRK: 57.46 (+0.25), PFE: 31.42 (-0.03), SRPT: 13.88 (+0.47), NLNK: 39.08 (+1.36), TKMR: 13.97 (+0.14), GSK: 42.85 (+0.11), NVS: 93.91 (+0.66)
TapImmune Provides Update on PolyStart(TM) Vaccine Platform Applicable to Cancer and Infectious Disease
Business Wire - Wed Oct 22, 7:30AM CDT
TapImmune, Inc. (OTCBB:TPIV), provides an update on the status of its PolyStart(TM) vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus. While the current focus of the Company's PolyStart technology is on TapImmune's cancer program (e.g., Her2/neu and folate receptor alpha antigens), the Company none-the-less strongly reaffirms that this core technology has widespread applicability in the development of vaccines for viral disease.
What's Next: Investors Place Ebola Pandemic Stock Bets
ACCESSWIRE - Mon Oct 06, 6:59AM CDT
Los Angeles, CA / October 6, 2014 / The recent outbreaks of Ebola in Africa and the first case found in the U.S. have also heightened the FDA's awareness of disease outbreaks and the need for stronger safety measures, but nothing gets investors salivating more that and constant media attention.
INO: 9.11 (-0.09), HEB: 0.22 (-0.02), TKMR: 13.97 (+0.14)
SeeThruEquity Issues Company Update on TapImmune Highlighting Positive Clinical Trial Data
ACCESSWIRE - Thu Sep 18, 8:03AM CDT
SeeThruEquity maintains price target of $6.97 per share and reiterates compelling valuation based on a number of factors including positive interim data on its Phase I clinical trial of folate receptor alpha antigens in ovarian and breast cancer
TapImmune Releases Positive Interim Data on Phase I Clinical Trial of Folate Receptor Alpha Antigens in Ovarian and Breast Cancer
Business Wire - Tue Sep 16, 7:30AM CDT
TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of 5 naturally processed folate receptor alpha Class II antigenic epitopes. All five of the constituent peptides were found to be immunogenic and all patients developed immune responses to at least one and in most cases more than one of the vaccine peptides.
TapImmune, Inc. to Present at SeeThruEquity Microcap Conference
ACCESSWIRE - Thu Sep 04, 8:01AM CDT
Seattle, WA / ACCESSWIRE / September 4, 2014 / TapImmune, Inc. (OTCQB: TPIV), announces that company executives will attend and present at the SeeThruEquity Microcap Investor Conference to be held Thursday September 11th at the Convene Times Square, New York City. The presentation is scheduled for 10:00AM ET.
TapImmune Inc to Present at 16th Annual Rodman & Renshaw Healthcare Conference
ACCESSWIRE - Wed Sep 03, 9:42AM CDT
Seattle WA / ACCESSWIRE / September 3, 2014 / TapImmune, Inc. (OTCQB: TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease, will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The presentation will take place Wednesday, September 10th at 2:30 p.m. EDT in the Kennedy I Salon (4th floor) at the New York Palace Hotel in New York City.
SeeThruEquity Issues Update Note on TapImmune Highlighting New Grant Funded Clinical Trial and Recent Capital Raise of $2 Million
ACCESSWIRE - Tue Aug 19, 7:51AM CDT
New York, NY / ACCESSWIRE / August 19, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (OTCQB: TPIV).
TapImmune, Inc. Announces $2 Million Registered Direct Offering
Business Wire - Mon Aug 11, 11:21AM CDT
TapImmune, Inc. (the "Company"
, (OTCQB:TPIV), today announced that it has entered into a definitive agreement with an institutional investor for a registered direct placement of $2,000,000 of common stock at a price of $1.06 per share. TapImmune's New Clinical Trial in Advanced Stage Ovarian Cancer Expands the Use of Folate Receptor Alpha Peptide Antigens
Business Wire - Thu Aug 07, 8:23AM CDT
TapImmune Inc. (OTCQB:TPIV) is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial ovarian cancer has started at the Mayo Clinic, Rochester, MN. The folate receptor alpha peptides being used in this study are the same ones that are being used in a current Phase I study in breast and ovarian cancer. Folate receptor alpha is over a 100 fold elevated in 90% of ovarian cancer cells and is thus an excellent target for immunotherapy.
TapImmune Prevails in Legal Dispute with Michael Gardner
Business Wire - Thu Jul 24, 8:38AM CDT
TapImmune Inc. (OTCQB:TPIV), announces successful outcome of proceedings against Michael Gardner after almost 2 years of litigation.
New Immunotherapy Technologies Provide Hope In Breast and Ovarian Cancer
ACCESSWIRE - Wed Jul 23, 7:06AM CDT
Los Angeles / ACCESSWIRE / July 23, 2014 / Last month, TapImmune Inc. (OTCQB: TPIV) announced that Dr. Keith Knutson, PhD had been appointed to chair the company's scientific advisory board.
SeeThruEquity Issues Company Note on TapImmune Highlighting Valuation as Compared with Peers
ACCESSWIRE - Tue Jul 01, 8:02AM CDT
New York, NY / ACCESSWIRE / July 1, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company note on TapImmune Inc. (OTCQB: TPIV).
JNJ: 104.59 (+0.31), KITE: 51.96 (+0.45), GALE: 1.49 (-0.02)
